ArticleAutoimmunity reviews2020
Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?
Article in Autoimmunity reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.Journal of translational autoimmunity · 2023Article
- Prevalence & Impact of COVID-19 in Systemic Sclerosis Patients and Assessment of the Demographic & Clinical Features in Cases Associated with Worse Prognosis: Results of a Single Centre Registry.Mediterranean journal of rheumatology · 2023Article
- [The impact of COVID-19 in a cohort of patients with systemic sclerosis].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.Seminars in arthritis and rheumatism · 2022Observational
- Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.Journal of clinical medicine · 2021Article
- COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort.Clinical rheumatology · 2021Article
- Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation.Journal of thrombosis and thrombolysis · 2021Review
- COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse?Autoimmunity reviews · 2020Article
- An Analysis Review of Detection Coronavirus Disease 2019 (COVID-19) Based on Biosensor Application.Sensors (Basel, Switzerland) · 2020Review
- COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.Clinical rheumatology · 2020Observational
- Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?Mediterranean journal of rheumatology · 2020Review
- The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak.Diagnostics (Basel, Switzerland) · 2020Article
- Covid-19 and autoimmunity.Autoimmunity reviews · 2020Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.